A Review of the Efficacy and Safety for Biologic Agents Targeting IL-23 in Treating Psoriasis With the Focus on Tildrakizumab
Psoriasis is a chronic and debilitating inflammatory immune-mediated skin disorder. Several cytokines including interleukin (IL)-23 were demonstrated to play a central role in the pathogenesis of this disease. Treatment options for psoriasis range from topical to systemic modalities, depending on th...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2021-08-01
|
| Series: | Frontiers in Medicine |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fmed.2021.702776/full |
| id |
doaj-c074309d4abc4647805c878939a96ab1 |
|---|---|
| record_format |
Article |
| spelling |
doaj-c074309d4abc4647805c878939a96ab12021-08-10T06:59:31ZengFrontiers Media S.A.Frontiers in Medicine2296-858X2021-08-01810.3389/fmed.2021.702776702776A Review of the Efficacy and Safety for Biologic Agents Targeting IL-23 in Treating Psoriasis With the Focus on TildrakizumabFeras M. Ghazawi0Farhan Mahmood1Leon Kircik2Yves Poulin3Marc Bourcier4Ronald Vender5Marni C. Wiseman6Charles Lynde7Ivan V. Litvinov8Division of Dermatology, University of Ottawa, Ottawa, ON, CanadaFaculty of Medicine, University of Ottawa, Ottawa, ON, CanadaDepartment of Dermatology, Mount Sinai Hospital, New York City, NY, United StatesDivision of Dermatology, Laval University, Quebec City, QC, CanadaFaculty of Medicine, University of Sherbrooke, Sherbrooke, QC, CanadaDivision of Dermatology, McMaster University, Hamilton, ON, CanadaSection of Dermatology, Department of Medicine, University of Manitoba, Winnipeg, MB, CanadaDivision of Dermatology, University of Toronto, Toronto, ON, CanadaDivision of Dermatology, McGill University, Montréal, QC, CanadaPsoriasis is a chronic and debilitating inflammatory immune-mediated skin disorder. Several cytokines including interleukin (IL)-23 were demonstrated to play a central role in the pathogenesis of this disease. Treatment options for psoriasis range from topical to systemic modalities, depending on the extent, anatomical locations involved and functional impairment level. Targeting cytokines or their cognate receptors that are involved in disease pathogenesis such as IL-12/23 (i.e., targeting the IL-12p40 subunit shared by these cytokines), IL-17A, IL-17F, IL-17RA, and TNF-α using biologic agents emerged in recent years as a highly effective therapeutic option for patients with moderate-to-severe disease. This review provides an overview of the important role of IL-23 signaling in the pathogenesis of psoriasis. We describe in detail the available IL-23 inhibitors for chronic plaque psoriasis. The efficacy, pharmacokinetic properties, and the safety profile of one of the most recent IL-23 biologic agents (tildrakizumab) are evaluated and reviewed in depth.https://www.frontiersin.org/articles/10.3389/fmed.2021.702776/fullpsoriaistreatmenttildrakizumabguselkumabIL-23risankizumab |
| collection |
DOAJ |
| language |
English |
| format |
Article |
| sources |
DOAJ |
| author |
Feras M. Ghazawi Farhan Mahmood Leon Kircik Yves Poulin Marc Bourcier Ronald Vender Marni C. Wiseman Charles Lynde Ivan V. Litvinov |
| spellingShingle |
Feras M. Ghazawi Farhan Mahmood Leon Kircik Yves Poulin Marc Bourcier Ronald Vender Marni C. Wiseman Charles Lynde Ivan V. Litvinov A Review of the Efficacy and Safety for Biologic Agents Targeting IL-23 in Treating Psoriasis With the Focus on Tildrakizumab Frontiers in Medicine psoriais treatment tildrakizumab guselkumab IL-23 risankizumab |
| author_facet |
Feras M. Ghazawi Farhan Mahmood Leon Kircik Yves Poulin Marc Bourcier Ronald Vender Marni C. Wiseman Charles Lynde Ivan V. Litvinov |
| author_sort |
Feras M. Ghazawi |
| title |
A Review of the Efficacy and Safety for Biologic Agents Targeting IL-23 in Treating Psoriasis With the Focus on Tildrakizumab |
| title_short |
A Review of the Efficacy and Safety for Biologic Agents Targeting IL-23 in Treating Psoriasis With the Focus on Tildrakizumab |
| title_full |
A Review of the Efficacy and Safety for Biologic Agents Targeting IL-23 in Treating Psoriasis With the Focus on Tildrakizumab |
| title_fullStr |
A Review of the Efficacy and Safety for Biologic Agents Targeting IL-23 in Treating Psoriasis With the Focus on Tildrakizumab |
| title_full_unstemmed |
A Review of the Efficacy and Safety for Biologic Agents Targeting IL-23 in Treating Psoriasis With the Focus on Tildrakizumab |
| title_sort |
review of the efficacy and safety for biologic agents targeting il-23 in treating psoriasis with the focus on tildrakizumab |
| publisher |
Frontiers Media S.A. |
| series |
Frontiers in Medicine |
| issn |
2296-858X |
| publishDate |
2021-08-01 |
| description |
Psoriasis is a chronic and debilitating inflammatory immune-mediated skin disorder. Several cytokines including interleukin (IL)-23 were demonstrated to play a central role in the pathogenesis of this disease. Treatment options for psoriasis range from topical to systemic modalities, depending on the extent, anatomical locations involved and functional impairment level. Targeting cytokines or their cognate receptors that are involved in disease pathogenesis such as IL-12/23 (i.e., targeting the IL-12p40 subunit shared by these cytokines), IL-17A, IL-17F, IL-17RA, and TNF-α using biologic agents emerged in recent years as a highly effective therapeutic option for patients with moderate-to-severe disease. This review provides an overview of the important role of IL-23 signaling in the pathogenesis of psoriasis. We describe in detail the available IL-23 inhibitors for chronic plaque psoriasis. The efficacy, pharmacokinetic properties, and the safety profile of one of the most recent IL-23 biologic agents (tildrakizumab) are evaluated and reviewed in depth. |
| topic |
psoriais treatment tildrakizumab guselkumab IL-23 risankizumab |
| url |
https://www.frontiersin.org/articles/10.3389/fmed.2021.702776/full |
| work_keys_str_mv |
AT ferasmghazawi areviewoftheefficacyandsafetyforbiologicagentstargetingil23intreatingpsoriasiswiththefocusontildrakizumab AT farhanmahmood areviewoftheefficacyandsafetyforbiologicagentstargetingil23intreatingpsoriasiswiththefocusontildrakizumab AT leonkircik areviewoftheefficacyandsafetyforbiologicagentstargetingil23intreatingpsoriasiswiththefocusontildrakizumab AT yvespoulin areviewoftheefficacyandsafetyforbiologicagentstargetingil23intreatingpsoriasiswiththefocusontildrakizumab AT marcbourcier areviewoftheefficacyandsafetyforbiologicagentstargetingil23intreatingpsoriasiswiththefocusontildrakizumab AT ronaldvender areviewoftheefficacyandsafetyforbiologicagentstargetingil23intreatingpsoriasiswiththefocusontildrakizumab AT marnicwiseman areviewoftheefficacyandsafetyforbiologicagentstargetingil23intreatingpsoriasiswiththefocusontildrakizumab AT charleslynde areviewoftheefficacyandsafetyforbiologicagentstargetingil23intreatingpsoriasiswiththefocusontildrakizumab AT ivanvlitvinov areviewoftheefficacyandsafetyforbiologicagentstargetingil23intreatingpsoriasiswiththefocusontildrakizumab AT ferasmghazawi reviewoftheefficacyandsafetyforbiologicagentstargetingil23intreatingpsoriasiswiththefocusontildrakizumab AT farhanmahmood reviewoftheefficacyandsafetyforbiologicagentstargetingil23intreatingpsoriasiswiththefocusontildrakizumab AT leonkircik reviewoftheefficacyandsafetyforbiologicagentstargetingil23intreatingpsoriasiswiththefocusontildrakizumab AT yvespoulin reviewoftheefficacyandsafetyforbiologicagentstargetingil23intreatingpsoriasiswiththefocusontildrakizumab AT marcbourcier reviewoftheefficacyandsafetyforbiologicagentstargetingil23intreatingpsoriasiswiththefocusontildrakizumab AT ronaldvender reviewoftheefficacyandsafetyforbiologicagentstargetingil23intreatingpsoriasiswiththefocusontildrakizumab AT marnicwiseman reviewoftheefficacyandsafetyforbiologicagentstargetingil23intreatingpsoriasiswiththefocusontildrakizumab AT charleslynde reviewoftheefficacyandsafetyforbiologicagentstargetingil23intreatingpsoriasiswiththefocusontildrakizumab AT ivanvlitvinov reviewoftheefficacyandsafetyforbiologicagentstargetingil23intreatingpsoriasiswiththefocusontildrakizumab |
| _version_ |
1721212710391119872 |